THC and Opiates: "Entourage Effect" of Prismic's IP-Protected Palmitoylethanolamide Drives New Prescription Drug Strategy
SCOTTSDALE, Ariz., Feb. 3, 2015 /PRNewswire/ -- Prismic Pharmaceuticals, Inc., a development-stage pharmaceutical company, today announced that it is expanding its product development focus to pursue FDA-approved prescription drugs as well as its current portfolio of prescription medical food products for chronic kidney disease (CKD) and for depression.
Prismic is now embarking on the development of palmitoylethanolamide, an endogenous fatty acid amide, as an FDA-approved prescription drug. This is a result of recent data confirming that certain formulations of its IP-protected palmitoylethanolamide demonstrate a clinical "entourage" or synergistic effect when administered in combination or concomitantly with certain target prescription products such as THC, oxycodone, morphine, and other opiates. The clinical benefit of the entourage effect is that lower doses of the target prescription drugs may be administered to achieve the desired therapeutic effect. This also means that there is a lessening or avoidance of adverse events and, in the case of opiates, a reduction in susceptibility to dependence and the delaying of the onset of tolerance.
Commenting on this new expanded strategy, Prismic's Chairman and CEO, Peter Moriarty, commented that "This is a key development for Prismic, and one which we believe the scientific and investment community will find of great interest because of the significant benefits that can be derived by patients. Clearly we have further clinical work to undertake in order to achieve our goal of securing FDA approval for these new, IP-protected palmitoylethanolamide-based products. As a consequence, we have started discussions with bankers and other investors regarding the most appropriate way forward to fund these new clinical initiatives as well as our existing close-to-market FDA-regulated prescription medical food products for CKD."
About Prismic Pharmaceuticals, Inc.
Prismic Pharmaceuticals, Inc. is a privately held, specialty pharmaceutical company engaged in the development and marketing of both prescription drugs and prescription medical foods. Its lead prescription drug candidates include IP-protected, dose-sparing palmitoylethanolamide-based products for combination or concomitant use with THC, oxycodone, morphine, and other opiates, as well as renal-sparing nephrology products for the clinical dietary management of pain and inflammation, and for the reduction of proteinuria in patients with CKD. The company, founded in 2011, is headquartered in Scottsdale, Arizona with offices in Boston, Massachusetts, and London, England. Contact 480.422.1810 or visit www.PrismicPharma.com
INFORMATION CONTACT
Peter Moriarty
Tel: 480.422.1810
SOURCE Prismic Pharmaceuticals, Inc.
Related Links
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article